Earnings call transcript: Eurogroup Laminations Q2 2025 sees modest growth

Eurogroup Laminations SpA (EGLA) reported Q2 2025 revenue up 1.6% to €429.2 million with a 10.4% EBITDA margin, and maintains a robust €5.1 billion order book. The company forecasts 5% FY2025 revenue growth and a 12% EBITDA margin, underpinned by a performance improvement program, despite facing headwinds from fragile European and weak North American markets, and delayed product launches. Crucially, EGLA announced a strategic alliance with EMS and Fulton Invest, which will acquire a 55.3% voting stake and launch a mandatory tender offer at €3.85/share by 2026, positioning the company for accelerated growth, particularly in the Chinese market.

Analysis

Eurogroup Laminations SpA (EGLA) reported a mixed Q2 2025, with modest revenue growth of 1.6% to €429.2 million, reflecting significant geographic divergence. While the Asian market, particularly China, remains a key growth driver, performance was dampened by fragile conditions in Europe and weakness in North America, which resulted in the postponement of three start-of-production (SOP) programs. EBITDA margin contracted to 10.4%, impacted by cost pressures and an unfavorable business mix, though management has launched a performance improvement plan to support its full-year guidance. The company reaffirmed its outlook for 5% revenue growth and an improved 12% EBITDA margin for the full year 2025, supported by a substantial €5.1 billion order book. The most pivotal development is the announced strategic alliance with EMS and Fulton Invest, which will acquire a 55.3% controlling stake and launch a mandatory tender offer at €3.85 per share. This transaction, expected to close by 2026, sets a valuation floor and strategically repositions the company to accelerate penetration into the Chinese OEM market, where it holds a €1.7 billion pipeline.

Key Decisions for Investors

• Investors should note the mandatory tender offer price of €3.85 per share, which provides a valuation anchor, while also considering the extended closing timeline into 2026 and associated regulatory hurdles.
• Monitor the execution of the company's performance improvement program and supply chain initiatives, as achieving the guided full-year EBITDA margin of 12% is contingent on their success and a stabilization of demand in Western markets.
• The strategic pivot towards China, facilitated by the new majority shareholders, presents a significant growth opportunity but also increases reliance on this single market; progress in converting the Chinese pipeline and securing local OEM contracts should be watched closely.
• Given the postponement of North American programs, scrutinize the conversion rate of the €5.1 billion order book and the ramp-up of remaining SOPs to validate the company's projected revenue growth.